JP2023549075A - 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 - Google Patents

自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 Download PDF

Info

Publication number
JP2023549075A
JP2023549075A JP2023526226A JP2023526226A JP2023549075A JP 2023549075 A JP2023549075 A JP 2023549075A JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023549075 A JP2023549075 A JP 2023549075A
Authority
JP
Japan
Prior art keywords
patient
nmosd
antibody
vib551
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549075A5 (enExample
Inventor
デュウェイ シェ
ジョン ラッチフォード
エリエゼル カッツ
ウィリアム リース
リ ヤン
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2023549075A publication Critical patent/JP2023549075A/ja
Publication of JP2023549075A5 publication Critical patent/JP2023549075A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023526226A 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 Pending JP2023549075A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (2)

Publication Number Publication Date
JP2023549075A true JP2023549075A (ja) 2023-11-22
JP2023549075A5 JP2023549075A5 (enExample) 2024-11-07

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526226A Pending JP2023549075A (ja) 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Country Status (10)

Country Link
US (1) US20230287114A1 (enExample)
EP (1) EP4237447A4 (enExample)
JP (1) JP2023549075A (enExample)
KR (1) KR20230097118A (enExample)
AU (1) AU2021368769A1 (enExample)
CA (1) CA3197022A1 (enExample)
IL (1) IL302294A (enExample)
MX (1) MX2023004794A (enExample)
TW (1) TW202233676A (enExample)
WO (1) WO2022094334A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006283A2 (en) * 2020-06-30 2022-01-06 Viela Bio, Inc. Methods of treating neuromyelitis optica spectrum disorder
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
AU2020263418A1 (en) * 2019-04-24 2021-11-11 Viela Bio, Inc. Use of an anti-CD19 antibody to treat autoimmune disease
WO2022006283A2 (en) * 2020-06-30 2022-01-06 Viela Bio, Inc. Methods of treating neuromyelitis optica spectrum disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANCET, vol. 394, JPN6025042506, 2019, pages 1352 - 1363, ISSN: 0005709750 *

Also Published As

Publication number Publication date
KR20230097118A (ko) 2023-06-30
AU2021368769A1 (en) 2023-06-08
US20230287114A1 (en) 2023-09-14
TW202233676A (zh) 2022-09-01
WO2022094334A1 (en) 2022-05-05
EP4237447A1 (en) 2023-09-06
CA3197022A1 (en) 2022-05-05
IL302294A (en) 2023-06-01
AU2021368769A9 (en) 2024-05-30
MX2023004794A (es) 2023-09-15
EP4237447A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
Prasad et al. What you need to know about AQP4, MOG, and NMOSD
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
JP2024543147A (ja) 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療
Wingerchuk Neuromyelitis optica spectrum disorders
AU2020263418A1 (en) Use of an anti-CD19 antibody to treat autoimmune disease
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
Duchow et al. Emerging drugs for the treatment of neuromyelitis optica
Tenembaum Pediatric demyelinating disease and anti‐MOG antibody
Bortoluzzi et al. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre
Gernert et al. Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
JP2023534916A (ja) 視神経脊髄炎スペクトラム障害を治療する方法
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病
CN116583538A (zh) 使用抗cd19抗体治疗自身免疫性疾病
Beyer et al. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings
In Cooperation with the Neuromyelitis Optica Study Group MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Wiśniewska et al. Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD)
Sharma et al. Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy
Akkus et al. Recent treatment guidelines and approach toward autoimmune encephalitis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
Fan et al. Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
TW202330022A (zh) 抗ｃｄ１９抗體治療重症肌無力之用途
Mariotto Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414